Navigation Links
Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Date:2/24/2011

HAYWARD, Calif., Feb. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced Paul Truex, Anthera's President and Chief Executive Officer, will present at Citi's 2011 Global Health Care Conference in New York, NY on Tuesday, March 1, 2011, at approximately 1:30 pm Eastern Time.Citi 2011 Global Health Care Conference PresentationDate/Time:

Tuesday, March 1, at 1:30 pm Eastern TimeLocation:

Hilton New YorkAbout Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.  Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2.  Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD).  Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
2. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
4. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
7. Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
8. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
9. Savient Pharmaceuticals Announces Executive Appointments
10. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
11. Webcast Alert: Isis Pharmaceuticals 2010 Financial Results and Highlights Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... Skeletal dysplasia is a group of rare diseases ... and cartilage. Its onset hits at the fetal ... mutation in the gene encoding fibroblast growth factor ... types of skeletal dysplasia, thanatophoric dysplasia (TD), a ... birth and is often lethal, and achondroplasia (ACH), ...
(Date:9/18/2014)... The quest for the ultimate memory device for computing ... at The City College of New York led by ... exhibit both magnetic and ferroelectric properties. , Combining both ... can occur between them and for the devices that ... Combining these two properties in a single material, however, ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Oxides discovered by CCNY team could advance memory devices 2
... Ala. , May 12 Atherotech Inc. will exhibit its ... Scientific Sessions 2010. The meeting takes place May 13-16 at ... , , ... lipid test that routinely reports directly measured LDL-C, which is included in ...
... ,, RESEARCH TRIANGLE PARK, N.C. , May 12 ... Research Clinical Trials and Statistics Unit, is running the Intergroup Exemestane Study ... women with early breast cancer and a median follow-up period of 91 ... the data from multiple centers. , ...
... Indiana Seed Fund, Indiana ,s only targeted life sciences seed ... Indianapolis -based biotechnology start-up company focused on the development of ... , , , ... 5 million Americans suffer from Alzheimer,s disease (AD), a number that ...
Cached Biology Technology:Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 2Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 3Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 3BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 4
(Date:9/18/2014)... and the Quebec government have discovered microplastics (in ... of Fisheries and Aquatic Sciences . , The ... industrial cleansers, to which they are commonly added ... buoyancy, they may readily pass through sewage treatment ... the world,s oceans, but have only recently been ...
(Date:9/18/2014)... Wis. No matter how many times it,s ... social, communicating creatures. , But by using ... organisms radically alter their behavior to suit their ... of them are present, and act accordingly. , ... millions, it may change from innocuous to pathogenic, ...
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... TROY, N.Y., Aug. 8 Milliseconds can mean the,difference ... sports,leading more trainers and athletes to look toward technology ... A fluids mechanics professor at Rensselaer Polytechnic Institute ... help,American swimmers sharpen their strokes, shave seconds from their ...
... than a fly buzzing around the house. South Africans have ... bunch of Roridula gorgonias leaves. Attracted to the ... is soon trapped by the natural flypaper. However, this is ... is home to a population of Pameridea roridulae ...
... between triumph and defeat in the world of Olympic ... technology as a tool to get an edge on ... Polytechnic Institute in Troy, N.Y., is using experimental flow ... shave seconds from their lap times, and race toward ...
Cached Biology News:'Top Secret' Technology To Help U.S. Swimmers Trim Times at Beijing Olympics 2'Top Secret' Technology To Help U.S. Swimmers Trim Times at Beijing Olympics 3How nonstick bugs evade natural fly paper 2'Top secret' technology to help US swimmers trim times at Beijing Olympics 2'Top secret' technology to help US swimmers trim times at Beijing Olympics 3
Fas-ligand rabbit polyclonal antibody...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: